IfM work on UK pharmaceutical supply chains scales up as project moves into next phase
The funding comes from Round 4 of the Advanced Manufacturing Supply Chain Initiative (AMSCI) and is matched by more than £11m from industry.
The REMEDIES project, launched in 2014, is headed up by GlaxoSmithKline with research led by the IfM’s Centre for International Manufacturing. It brings together key players in the end-to-end supply chain, including major contract manufacturing organisations, equipment manufacturers along with regulators, knowledge transfer networks and healthcare providers.
The project, due to be completed in March 2018, has several technology based application projects underpinned by two platform projects: clinical trials supply chains, led by GSK, and commercial supply chains led by IfM. This new announcement means that the project can move into the technology application phase.
Jag Srai, Head of CIM and REMEDIES Research Director, said: “Now the government funding has been approved, we can build on the considerable amount of progress made in the design of these production and supply chain transformative technologies, enabling investments in expertise and capital across the projects led by our industrial partners.”
Mike Gregory said:
“CIM has been at the forefront of research into the impact of disruptive technologies and new business models on supply networks in key sectors. It is very pleasing to see this work playing such a pivotal part in the REMEDIES project.”
Professor David Cardwell, Head of the University of Cambridge Department of Engineering, said:
“Life sciences have always been an integral part of the ‘Cambridge Phenomenon’ and with the Precision Medicine Catapult now established here and the arrival of AstraZeneca’s global HQ imminent, Cambridge is rapidly becoming the centre of pharmaceutical research and development in the UK. I am delighted that the IfM is supporting this trend with its leading role in the REMEDIES project, in which researchers and industrial partners are working together to make a significant contribution to this globally important sector.”
More information on the REMEDIES project and partner organisations is shown here: www.remediesproject.com